a big blow to women who suffer from female sexual dysfunction

Following the setback from the United States Food & Drug Administration who decided that flibanserin didn't make the grade to get full approval for sale and marketing, its manufacturer Boehringer Ingelheim has decided to pull the plug on further research and development. This announcement will come as a big blow to women who suffer from female sexual dysfunction around the world especially those who had hoped that flibanserin would have been the female equivalent of Viagra.

Flibanserin which was first tested as an antidepressant functions by increasing levels of dopamine and norepinephrin in the brain and reducing levels of serotonin. Boehringer Ingelheim said that even they didn't fully understand exactly why flibanserin had an effect on levels of female sexual desire despite investing millions of pounds in research and development.

The reason why so much cash is going into drugs to treat female sexual dysfunction is because the market is known to be worth well over £1 billion every year, and could provide the same sort of boost to profits as Viagra provided for Pfizer. Recently Ukmedix News reported that Bayer had invested hundreds of millions of dollars in a new topical treatment for female sexual problems.

So, for now ladies you will have to make do with the drug Intrinsa which is applied in the way of a patch that releases small amounts of testosterone into the bloodstream. Intrinsa that is a prescription medication has shown to boost levels of sexual desire in post menopausal women and is the only prescription medication available in the United Kingdom for the treatment of this condition.

At Ukmedix News we have always advised that female sexual dysfunction is very different from male erectile dysfunction especially because the former tends to be caused by emotional and psychological issues rather than purely physical one as in the case of men.